Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials

OncoTargets and Therapy ◽

10.2147/ott.s103954 ◽

2016 ◽

Vol Volume 9 ◽

pp. 3771-3781 ◽

Cited By ~ 3

Author(s):

Xiao-Qun Liu ◽

Xiangdong Liu ◽

Tiankui Qiao ◽

Wei Chen ◽

Sujuan Yuan

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Controlled Trials ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Randomized Controlled ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text

Efficacy and safety of bevacizumab in combination with docetaxel for the first-line treatment of elderly patients with locally recurrent or metastatic breast cancer: Results from AVADO

European Journal of Cancer ◽

10.1016/j.ejca.2011.06.018 ◽

2011 ◽

Vol 47 (16) ◽

pp. 2387-2395 ◽

Cited By ~ 61

Author(s):

Xavier Pivot ◽

Andreas Schneeweiss ◽

Shailendra Verma ◽

Christoph Thomssen ◽

José Luis Passos-Coelho ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Elderly Patients ◽

Metastatic Breast ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text

The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials

Tumor Biology ◽

10.1007/s13277-014-1635-4 ◽

2014 ◽

Vol 35 (5) ◽

pp. 4841-4848 ◽

Cited By ~ 2

Author(s):

Xuan Wang ◽

Chun Huang ◽

Man Li ◽

Yanjun Gu ◽

Yanfen Cui ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Randomized Controlled Trials ◽

Meta Analysis ◽

Metastatic Breast ◽

Controlled Trials ◽

Line Treatment ◽

First Line ◽

Randomized Controlled ◽

First Line Treatment

Download Full-text

Comment on Wang et al.: The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials

Tumor Biology ◽

10.1007/s13277-014-1924-y ◽

2014 ◽

Vol 35 (7) ◽

pp. 6183-6183 ◽

Cited By ~ 2

Author(s):

Jun Li ◽

Yunfeng Yao ◽

Juehua Jing

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Randomized Controlled Trials ◽

Meta Analysis ◽

Metastatic Breast ◽

Controlled Trials ◽

Line Treatment ◽

First Line ◽

Randomized Controlled ◽

First Line Treatment

Download Full-text

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

European Journal of Cancer ◽

10.1016/j.ejca.2014.10.008 ◽

2014 ◽

Vol 50 (18) ◽

pp. 3077-3088 ◽

Cited By ~ 16

Author(s):

S.W. Lam ◽

S.M. de Groot ◽

A.H. Honkoop ◽

A. Jager ◽

A.J. ten Tije ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text

Phase II Study of Gemcitabine and Bevacizumab As First-Line Treatment in Taxane-Pretreated, HER2-Negative, Locally Recurrent or Metastatic Breast Cancer

Clinical Breast Cancer ◽

10.1016/j.clbc.2012.07.004 ◽

2012 ◽

Vol 12 (5) ◽

pp. 322-330 ◽

Cited By ~ 5

Author(s):

Rachel Borson ◽

Graydon Harker ◽

James Reeves ◽

Thaddeus Beck ◽

Steven Hager ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text

Phase II study of gemcitabine (G) and bevacizumab (B) as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer (MBC): Interim safety analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.1148 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 1148-1148

Author(s):

R. Borson ◽

W. G. Harker ◽

J. E. Reeves ◽

J. Bromund ◽

L. Zhao ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Safety Analysis ◽

Line Treatment ◽

First Line ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text

Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): Results from a phase II, single-arm, multicenter study.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.635 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 635-635

Author(s):

Shannon Puhalla ◽

Sharon Wilks ◽

Adam Brufsky ◽

Joyce O'Shaughnessy ◽

Lee Steven Schwartzberg ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Multicenter Study ◽

Metastatic Breast ◽

Clinical Effects ◽

Line Treatment ◽

First Line ◽

Eribulin Mesylate ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text

Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer

Journal of Clinical Oncology ◽

10.1200/jco.20.3.719 ◽

2002 ◽

Vol 20 (3) ◽

pp. 719-726 ◽

Cited By ~ 1152

Author(s):

C. L. Vogel

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Single Agent ◽

Metastatic Breast ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

First Line Treatment

Download Full-text

The Breast Avastin Trial: phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-013-2100-6 ◽

2013 ◽

Vol 71 (4) ◽

pp. 1051-1057 ◽

Cited By ~ 13

Author(s):

G. Bisagni ◽

A. Musolino ◽

M. Panebianco ◽

A. De Matteis ◽

F. Nuzzo ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Maintenance Therapy ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Locally Recurrent ◽

Trial Phase ◽

First Line Treatment

Download Full-text

Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First‐Line Treatment for HER‐2‐positive Locally Recurrent or Metastatic Breast Cancer

The Oncologist ◽

10.1634/theoncologist.2011-0344 ◽

2012 ◽

Vol 17 (4) ◽

pp. 469-475 ◽

Cited By ~ 34

Author(s):

Miguel Martín ◽

Anatoly Makhson ◽

Joseph Gligorov ◽

Mikhail Lichinitser ◽

Ana Lluch ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Her 2 ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text